IMMP
- Immutep Limited
()
Overview
Company Summary
Immutep Limited (IMMP) is a biotechnology company that specializes in the development of immunotherapy treatments for cancer and autoimmune diseases. The company focuses on developing innovative drugs that stimulate the immune system to fight against diseases.
Immutep's core technology is based on a group of proteins called Lymphocyte Activation Gene-3 (LAG-3). LAG-3 plays a crucial role in the regulation of T cells, which are a type of immune cells responsible for identifying and attacking abnormal cells, such as cancer cells.
Immutep has developed a range of product candidates designed to activate LAG-3 and enhance T-cell responses. This includes therapeutic antibodies that directly target LAG-3 as well as small molecule compounds that modulate LAG-3 signaling.
The company's lead product candidate is called eftilagimod alpha (efti) and is being developed for the treatment of various types of cancer. Efti works by activating the immune system to recognize and destroy cancer cells more effectively. Immutep is conducting clinical trials to evaluate the safety and efficacy of efti, both as a standalone treatment and in combination with other cancer therapies.
In addition to its cancer immunotherapy pipeline, Immutep is also developing treatments for autoimmune diseases using its LAG-3 technology. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells in the body. By modulating LAG-3 signaling, Immutep aims to restore immune system balance and alleviate symptoms associated with these diseases.
Overall, Immutep Limited is dedicated to advancing the field of immunotherapy and developing innovative treatments that harness the power of the immune system to fight cancer and autoimmune diseases.